What is claimed is:

1. Use of a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof that specifically binds human epidermal growth factor receptor (hEGFR) in the manufacture of a medicament for inhibiting tumor growth in a subject afflicted with a tumor, wherein the antibody or antigen-binding fragment thereof comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:130, and (b) the CDRs of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:138.

2. The use of claim 1, wherein the antibody or antigen-binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair having SEQ ID NOs: 130/138.

3. The use of claim 2, wherein the antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 domains, respectively, having SEQ ID NOs: 132, 134, 136, 140, 142, and 144.

4. The use of claim 1, wherein the tumor is selected from the group consisting of a renal tumor, a pancreatic tumor, a head and neck tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, an ovarian tumor, a lung tumor, and a skin tumor.

5. The use of claim 1, further comprising a second therapeutic agent.

6. The use of claim 5, wherein the second therapeutic agent is an antibody or antigen-binding fragment thereof that specifically binds HER2, ErbB3, ErbB4, cMet, IGF1R, Ang2, PDGFR-α or PDGFR-β.

7. The use of claim 5, wherein the second therapeutic agent is a VEGF antagonist.

8. The use of claim 7, wherein the VEGF antagonist is a VEGF-Trap.

9. The use of claim 7, wherein the VEGF antagonist is an anti-VEGF antibody.

10. The use of claim 9, wherein the anti-VEGF antibody is bevacizumab.

11. The use of claim 7, wherein the VEGF antagonist is a small molecule kinase inhibitor of VEGF receptor.

12. The use of claim 11, wherein the small molecule kinase inhibitor of VEGF receptor is sunitinib, sorafenib or pazopanib.

13. The use of claim 1, wherein the antibody or antigen-binding fragment thereof is to be administered as part of a treatment regimen that also includes radiation treatment and/or conventional chemotherapy.